Stay updated on BCD-020 Safety & Efficacy in Indolent NHL Clinical Trial
Sign up to get notified when there's something new on the BCD-020 Safety & Efficacy in Indolent NHL Clinical Trial page.

Latest updates to the BCD-020 Safety & Efficacy in Indolent NHL Clinical Trial page
- Check3 days agoChange DetectedThe page’s revision/version indicator was updated from v3.5.2 to v3.5.3, reflecting a change to the site’s interface release rather than the underlying study details.SummaryDifference0.0%

- Check10 days agoChange DetectedAdded Revision: v3.5.2; Deleted Revision: v3.5.0.SummaryDifference0.0%

- Check17 days agoNo Change Detected
- Check31 days agoChange DetectedFollicular lymphoma was added to the conditions section and the Genetic and Rare Diseases Information Center resources reference was included.SummaryDifference0.1%

- Check39 days agoChange DetectedRevision updated to v3.5.0, replacing the previous v3.4.3 entry.SummaryDifference0.0%

- Check53 days agoChange DetectedRevision updated from v3.4.2 to v3.4.3.SummaryDifference0.0%

- Check74 days agoChange DetectedThe page shows a new UI revision label 'Revision: v3.4.2' replacing the previous 'Revision: v3.4.1'. To avoid being alerted by small changes, set an alert condition by clicking below.SummaryDifference0.0%

Stay in the know with updates to BCD-020 Safety & Efficacy in Indolent NHL Clinical Trial
Enter your email address, and we'll notify you when there's something new on the BCD-020 Safety & Efficacy in Indolent NHL Clinical Trial page.